Pharma industry urges Budget reforms for R&D incentives, regulatory simplification, and enhanced healthcare spending to boost ...

In a bid to reclaim market share, India is expanding its pharmaceutical exports to Afghanistan, focusing on providing ...

India’s pharmaceutical exports reached $30.47 billion in FY 2024–25, registering a 9.4 per cent year-on-year growth, and are ...

Indian speciality pharmaceutical firm Ajanta Pharma is understood to be eyeing a manufacturing operation in Ireland. The ...

Sun Pharma's Managing Director, Kirti Ganorkar, predicts that new age medicines for obesity and diabetes will drive the growth of the domestic pharmaceutical industry.

In FY25, India's pharmaceutical exports reached a record high, surpassing $30 billion (approximately $30.47 billion), a ...

India’s pharmaceutical exports reached US$ 30.47 billion in FY 2024–25, and the sector remains optimistic about further growth, driven by strong global demand and resilient production capabilities.

The year also reinforced a long-standing strength of Indian pharma: its ability to scale through strategic consolidation.

Jubilant Biosys Limited. Jubilant Biosys Doubles Early Chemistry Scale-Up Capacity with New Noida Facility in India. Press ...

Union Budget 2026–27 presents an opportunity to address a consequential constraint on India’s upstream manufacturing ...

Access to new-age medicines for obesity and diabetes is crucial for the Indian pharmaceutical industry's growth. Combined with AI tools, this will support accessibility and affordability. India aims ...

With the right policy support, the sector can reach a size of USD 120-130 billion by 2030, and expand further to about USD ...